This study assesses the cost-effectiveness of adding a sodium-glucose cotransporter 2 inhibitor versus switching to a glucagon-like peptide-1 receptor agonist in patients with diabetes on metformin and a dipeptidyl peptidase-4 inhibitor.
Anna Hung, PharmD, PhD
Advertisement
Articles by Anna Hung, PharmD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week
2
Clesrovimab Demonstrates Safety Through a Second RSV Season in High-Risk Infants
3
Dry Eye Disease Is More Than "Dry Eyes": Experts Explain the 2 Types
4
Multidisciplinary Teams Improve Biomarker Testing and Lung Cancer Care: Urs Weber, MD
5